ONX-0914 (PR-957): Selective Immunoproteasome LMP7 Inhibitor for Autoimmune and Inflammatory Disease Research

Executive Summary: ONX-0914 (PR-957) is a potent and highly selective inhibitor of the immunoproteasome LMP7 subunit, enabling precise modulation of immune pathways implicated in autoimmunity and inflammation (Schaunaman et al. 2025). It blocks proinflammatory cytokine production in human and mouse models without significant off-target effects on the constitutive proteasome (APExBIO). ONX-0914 demonstrates robust efficacy in vitro and in vivo, including in models of diabetes, arthritis, and colitis (MG-132.com). Its distinct mechanism supports reproducible results in established and emerging immune research workflows, extending beyond traditional proteasome inhibitors. The product is supplied by APExBIO and optimized for research reproducibility, sensitivity, and workflow integration.

Biological Rationale

The immunoproteasome (IP) is a specialized proteolytic complex induced by pro-inflammatory cytokines such as interferon gamma (IFN-γ). The IP replaces specific subunits of the constitutive proteasome with LMP2, MECL-1, and LMP7, conferring unique peptide cleavage preferences crucial for antigen presentation and regulation of immune responses (Schaunaman et al. 2025). Dysregulation of immunoproteasome activity is implicated in autoimmune pathologies, chronic inflammation, and impaired cytokine homeostasis. In particular, LMP7 (β5i) is central to the degradation of inflammatory mediators and maintenance of immune tolerance. Inhibition of LMP7 alters cytokine profiles and immune cell activity, providing a rationale for targeting this subunit in experimental and translational research on autoimmunity, airway hyperresponsiveness, and chronic inflammatory diseases.

Mechanism of Action of ONX-0914 (PR-957)

ONX-0914, also known as PR-957, is a tripeptide epoxyketone inhibitor that covalently and selectively binds the S1 pocket of LMP7 (β5i), sparing the constitutive proteasome β5 subunit in both human and murine cells (APExBIO). This selectivity is confirmed by biochemical and structural assays: ONX-0914 induces conformational changes in LMP7, preventing its proteolytic activity without significantly affecting non-immunoproteasome proteolysis. Through LMP7 inhibition, ONX-0914 blocks the generation of proinflammatory cytokines including IL-23, TNF-α, and IL-6 in peripheral blood mononuclear cells (PBMCs). In vitro, it suppresses differentiation of IL-17-producing T cells (TH17) under polarizing conditions, and in vivo, it attenuates disease severity in murine models of diabetes, collagen-induced arthritis, and DSS-induced colitis (MG-132.com). ONX-0914 also alters the degradation of key immune receptors such as IL-4Rα, thereby modulating type 2 inflammatory pathways (Schaunaman et al. 2025).

Evidence & Benchmarks

• ONX-0914 inhibits LMP7 activity with high selectivity, not significantly affecting the constitutive β5 subunit in human or mouse cells (APExBIO).
• In human airway epithelial cells, ONX-0914 increases IL-4Rα expression and eotaxin-3 release following IL-13 stimulation, confirming its functional impact on type 2 inflammation pathways (Schaunaman et al. 2025).
• In murine models, ONX-0914 administration (2–10 mg/kg IV) produces dose-dependent reductions in autoantibody titers, cartilage breakdown markers, and disease progression in arthritis, diabetes, and colitis (MG-132.com).
• In vitro, ONX-0914 at 200 nM for 1 hour effectively suppresses proinflammatory cytokine production and TH17 differentiation in PBMCs (PS-341.com).
• ONX-0914 is highly soluble in DMSO (≥29.03 mg/mL) and ethanol (≥69 mg/mL), but insoluble in water, facilitating implementation in standard cell and animal workflows (APExBIO).
• IP inhibition by ONX-0914 in human precision-cut lung slices (PCLS) increases airway hyperresponsiveness and inflammatory mediator release, validating its pharmacodynamic effects (Schaunaman et al. 2025).

This article extends recent summaries of ONX-0914's immune regulatory effects (PS-341.com) by integrating new evidence from airway and type 2 inflammation models, as detailed in Schaunaman et al. 2025.

Applications, Limits & Misconceptions

ONX-0914 is a preferred tool for dissecting immunoproteasome function in autoimmunity, chronic inflammation, and cytokine modulation. It is widely used in research models of:

• Rheumatoid arthritis (collagen-induced and spontaneous autoimmune models)
• Type 1 diabetes (NOD mice)
• Colitis (DSS- and T cell transfer-induced)
• Asthma and airway hyperresponsiveness (PCLS and epithelial cell models)

It is also valuable for exploring caspase-independent cell death pathways and antigen presentation. Unlike broad-spectrum proteasome inhibitors, ONX-0914 offers selectivity that aids interpretation of immune-specific mechanisms (PalonosetronAPI.com). This article clarifies recent findings on ONX-0914's use in airway inflammation, extending prior work focused on autoimmunity and neuroinflammation.

Common Pitfalls or Misconceptions

• ONX-0914 is not effective in models where immunoproteasome expression is minimal or absent, such as certain non-inflammatory tissues.
• It does not induce broad cytotoxicity at standard working concentrations (≤200 nM in vitro; ≤10 mg/kg IV in vivo), but higher doses or prolonged exposure can affect cell viability.
• ONX-0914 is insoluble in water—improper solvent use can result in precipitation or loss of activity.
• It does not target the constitutive proteasome β5 subunit; effects observed in such contexts may be off-target or unrelated to LMP7 inhibition.
• Therapeutic effects in animal models do not directly translate to clinical efficacy without further validation.

Workflow Integration & Parameters

For cell-based experiments, ONX-0914 is typically prepared at 200 nM in DMSO, with a 1-hour incubation at 37°C. For animal studies, intravenous administration at 2–10 mg/kg is standard, with dose-dependent effects observed. Solutions should be freshly prepared and stored at -20°C; avoid long-term storage. ONX-0914 is compatible with standard immunoassays, cytokine profiling, flow cytometry, and histopathological analysis. The compound’s high solubility in DMSO and ethanol supports flexible experimental design. For detailed troubleshooting and workflow optimization, see scenario-driven protocols (PrecisionFDA.com), which this article updates by highlighting new data on airway inflammation and PCLS models.

For ordering and technical documentation, refer to the ONX-0914 (PR-957) product page (SKU A4011) by APExBIO.

Conclusion & Outlook

ONX-0914 (PR-957) is a validated, selective immunoproteasome (LMP7) inhibitor enabling precise manipulation of cytokine production and immune regulation in vitro and in vivo. Peer-reviewed evidence supports its utility in dissecting autoimmune, inflammatory, and airway disease mechanisms. Integration into diverse research workflows is robust, with reproducible effects and well-characterized parameters. Ongoing studies are refining its application in complex disease models and translational research. For expanded insights into advanced mechanisms and airway epithelium, see updated reviews (OctocryleneChem.com), which this article builds upon by consolidating new translational findings.